CEO Samuel J. Reich to Speak at Major Healthcare Conference
SAB BIO (NASDAQ: SABS), a cutting-edge biopharmaceutical company focused on innovative immunotherapy solutions, has announced that its Chairman and CEO, Samuel J. Reich, will be participating in a fireside chat at the upcoming Guggenheim Securities Healthcare Innovation Conference. This much-anticipated event will take place over three days, providing a fantastic opportunity for industry insights and networking.
Fireside Chat Details and What to Expect
The fireside chat is scheduled for November 11 at 3:00 PM EST. SAB BIO aims to utilize this platform to showcase significant advancements related to its clinical-stage projects, particularly in relation to type 1 diabetes (T1D). By sharing its insights and experiences, the company hopes to foster dialogue about the future of immunotherapy treatments in healthcare.
Innovative Therapeutics: Advancing Diabetes Treatment
SAB BIO is well-known for its pioneering approach to immunoglobulin development using its unique genetic engineering techniques. Their lead asset, SAB-142, works towards modifying T1D treatment approaches. With a focus on delays to disease onset and aiming for progress prevention, the company is pushing the boundaries of current medical technologies.
Webcast and Accessibility of Information
The fireside chat will be available via webcast, enabling remote audiences to engage with the conference's content. Interested parties can register to view the live presentation, after which a recording will also be accessible on the SAB BIO website. This ensures that even those unable to attend the event can catch up on the discussions and insights shared by industry leaders.
About SAB BIO: A Leader in Immunotherapy Development
SAB BIO is characterized by its commitment to creating high-potency immunoglobulins that can actively treat and prevent autoimmune conditions without the reliance on human donors or convalescent plasma. Their innovative DiversitAb™ platform harnesses the potential of Transchromosomic (Tc) Bovine™, providing a reliable source for developing a wide array of human IgG therapeutics. This novel approach stands to address numerous unmet medical needs.
Contact Information for Further Inquiries
For media inquiries, SAB BIO is represented by Kaelan Hollon, the Vice President of Communications. For investor relations, Kevin Gardner and Chris Calabrese of LifeSci Advisors are available to provide additional insights into the company's strategies and future plans.
Frequently Asked Questions
What is SAB BIO presenting at the Guggenheim Healthcare Conference?
SAB BIO will present advancements in their immunotherapy platform and discuss the impact of their lead asset, SAB-142, on type 1 diabetes treatment.
When is the fireside chat scheduled?
The fireside chat is scheduled for November 11 at 3:00 PM EST.
How can I access the webcast of the event?
You can register for the webcast on SAB BIO's website to view the live discussion and access recorded material later.
What is the focus of SAB BIO's research?
SAB BIO focuses on developing human, multi-targeted immunoglobulins aimed at treating and preventing autoimmune disorders.
Who can I contact for more information?
You can reach out to media contact Kaelan Hollon or investor relations contacts Kevin Gardner and Chris Calabrese for further inquiries.